KRAS as prognostic biomarker in metastatic colorectal cancer patients treated with bevacizumab: a pooled analysis of 12 published trials

Petrelli, Fausto; Coinu, Andrea; Cabiddu, Mary; Ghilardi, Mara; Barni, Sandro
September 2013
Medical Oncology;Sep2013, Vol. 30 Issue 3, p1
Academic Journal
No abstract available.


Related Articles

  • Correlation of bevacizumab-induced hypertension and outcomes of metastatic colorectal cancer patients treated with bevacizumab: a systematic review and meta-analysis. Jun Cai; Hong Ma; Fang Huang; Dichao Zhu; Jianping Bi; Yang Ke; Tao Zhang // World Journal of Surgical Oncology;2013, Vol. 11 Issue 1, p1 

    Background With the wide application of targeted drug therapies, the relevance of prognostic and predictive markers in patient selection has become increasingly important. Bevacizumab is commonly used in combination with chemotherapy in the treatment of metastatic colorectal cancer. However,...

  • Evaluating the treatment of metastatic colorectal cancer with monoclonal antibodies. Popa, C.; Ionescu, S.; Mihaila, D.; Gal, I.; Poteca, T. // Journal of Medicine & Life;Apr-Jun2012, Vol. 5 Issue 2, p168 

    The ability to tailor biologic therapy based on the status of tumor biomarkers and monoclonal antibodies has become very important in the last years. The role of tumor biomarkers in treating colorectal cancer, specifically the K-RAS gene, was identified. KRAS had a higher interest after Lievre...

  • Role of Kras Status in Patients with Metastatic Colorectal Cancer Receiving First-Line Chemotherapy plus Bevacizumab: A TTD Group Cooperative Study. Díaz-Rubio, Eduardo; Gómez-España, Auxiliadora; Massutí, Bartomeu; Sastre, Javier; Reboredo, Margarita; Manzano, JoséLuis; Rivera, Fernando; Safont, Ma José; Montagut, Clara; González, Encarnación; Benavides, Manuel; Marcuello, Eugenio; Cervantes, Andrés; de Prado, Purificación Martínez; Fernández-Martos, Carlos; Arrivi, Antonio; Bando, Inmaculada; Aranda, Enrique // PLoS ONE;Oct2012, Vol. 7 Issue 10, Special section p1 

    Background: In the MACRO study, patients with metastatic colorectal cancer (mCRC) were randomised to first-line treatment with 6 cycles of capecitabine and oxaliplatin (XELOX) plus bevacizumab followed by either single-agent bevacizumab or XELOX plus bevacizumab until disease progression. An...

  • Metastatic colorectal cancer first-line treatment with bevacizumab: the impact of K-ras mutation. Rossi, Luigi; Veltri, Enzo; Zullo, Angelo; Zoratto, Federica; Colonna, Maria; Longo, Flavia; Mottolese, Marcella; Giannarelli, Diana; Ruco, Luigi; Marchetti, Paolo; Romiti, Adriana; Barucca, Viola; Giannini, Giuseppe; Bianchi, Loredana; Tomao, Silverio // OncoTargets & Therapy;2013, Vol. 6, p1761 

    Background: Bevacizumab plus chemotherapy prolongs progression-free survival (PFS) and overall survival (OS) in metastatic colorectal cancer (mCRC). Although there is strong evidence to suggest that the mutational status of the K-ras oncogene has a role as a predictive factor for activity in...

  • Dose KRAS Mutation Status Affect on the Effect of VEGF Therapy in Metastatic Colon Cancer Patients? Seung Tae Kim; Kyong Hwa Park; Sang Won Shin; Yeul Hong Kim // Cancer Research & Treatment;Jan2014, Vol. 46 Issue 1, p48 

    Purpose: Mutations affecting the KRAS gene are an established negative predictor for antiepidermal growth factor receptor (anti-EGFR) therapies in metastatic colorectal cancer (CRC). However, the role of KRAS mutation as a biomarker for anti-vascular endothelial growth factor (VEGF) remains...

  • An Australian translational Study to evaluate the prognostic role of inflammatory markers in patients with metastatic ColorEctal caNcer Treated with bevacizumab (Avastin™) [ASCENT]. Clarke, Stephen; Burge, Matt; Cordwell, Cassandra; Gibbs, Peter; Reece, William; Tebbutt, Niall // BMC Cancer;2013, Vol. 13 Issue 1, p1 

    Background: The use of bevacizumab in combination with fluoropyrimidine-containing chemotherapy is a wellestablished first-line and second-line treatment for patients with metastatic colorectal cancer (mCRC). However, there remains a need for reproducible, validated, inexpensive and accessible...

  • Association of k-ras, b-raf, and p53 Status With the Treatment Effect of Bevacizumab. Ince, William L.; Jubb, Adrian M.; Holden, Scott N.; Holmgren, Eric B.; Tobin, Patti; Sridhar, Meera; Hurwitz, Herbert I.; Kabbinavar, Fairooz; Novotny, William F.; Hillan, Kenneth J.; Koeppen, Hartmuth // JNCI: Journal of the National Cancer Institute;7/6/2005, Vol. 97 Issue 13, p981 

    Background: A recent phase III trial showed that the addition of bevacizumab, a monoclonal antibody to vascular endothelial growth factor-A, to first-line irinotecan, 5-fluorouracil, and leucovorin (IFL) prolonged median survival in patients with metastatic colorectal cancer. We carried out a...

  • KRAS status predicted panitumumab response.  // Hem/Onc Today;12/10/2008, Vol. 9 Issue 22, p37 

    The article reports on the results of four clinical studies which aimed to determine the efficacy of panitumumab monotherapy in relation to KRAS mutational status for treating metastatic colorectal cancer. Findings show that KRAS appears to be a valid biomarker for determining which patients...

  • Use of Bevacizumab in Metastatic Colorectal Cancer. Zinser-Sierra, Juan W.; Rodríguez-Ramírez, Saúl; Villalobos-Valencia, Ricardo; Ramíez-Márquez, Marcelino // Drugs in R&D;2011, Vol. 11 Issue 2, p101 

    Colorectal cancer is one of the most common cancers worldwide, and although associated mortality rates in South American countries are generally among the lowest in the world, they are on the rise. The prognosis of patients diagnosed with metastatic colorectal cancer has improved markedly over...

  • Efficacy and Safety of Bevacizumab in Metastatic Colorectal Cancer: Pooled Analysis From Seven Randomized Controlled Trials. Hurwitz, Herbert I.; Tebbutt, Niall C.; Kabbinavar, Fairooz; Giantonio, Bruce J.; Guan, Zhong‐Zhen; Mitchell, Lada; Waterkamp, Daniel; Tabernero, Josep // Oncologist;Sep2013, Vol. 18 Issue 9, p1004 

    Purpose. This analysis pooled individual patient data from randomized controlled trials (RCTs) to more thoroughly examine clinical outcomes when adding bevacizumab to chemotherapy for patients with metastatic colorectal cancer (mCRC). Patients and Methods. Patient data were pooled from the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics